Trial Profile
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Duodenal cancer; Intestinal cancer
- Focus Therapeutic Use
- Acronyms ZEBRA
- 13 Jun 2022 Planned End Date changed from 1 Jun 2022 to 31 Mar 2024.
- 12 Apr 2021 Results published in the Clinical Cancer Research
- 24 Jun 2020 Results assessing biomarker levels predicting levels of Bim and CX3CR1/granzyme B in CD8+ T cells presented at the 111th Annual Meeting of the American Association for Cancer Research - II